Oral Prednisone Is Not Recommended for Routine Osteoarthritis Management

Guideline Recommendations

The National Institute for Health and Care Excellence (NICE) (2008) recommends a stepwise pharmacologic hierarchy for adults with osteoarthritis that excludes oral corticosteroids: first‑line paracetamol (acetaminophen) or topical NSAIDs; second‑line oral NSAIDs or COX‑2 inhibitors combined with a proton‑pump inhibitor; and intra‑articular corticosteroid injection only for moderate‑to‑severe pain during acute flares【1】.
The European League Against Rheumatism (EULAR) (2000, 2003) advises intra‑articular steroid injections for acute exacerbations—especially when joint effusion is present—but does not endorse oral corticosteroids for osteoarthritis management【6】【7】【8】【9】【10】.
The American College of Rheumatology/Arthritis Foundation (ACR/AF) (2019) issues a strong recommendation for intra‑articular glucocorticoid injections in knee osteoarthritis and explicitly refrains from recommending oral corticosteroids【5】.

Meta‑analytic data from EULAR‑referenced trials show that a single intra‑articular corticosteroid injection yields a large short‑term pain‑relief effect (standardized mean difference ≈ 1.27 at 7 days) with a markedly lower risk of systemic adverse events compared with oral steroids【6】【7】【8】【9】.
Intra‑articular injections are particularly effective for acute osteoarthritis exacerbations accompanied by joint effusion, providing rapid symptom control without systemic exposure【6】【9】.

All cited guidelines (NICE 2008 and ACR/AF 2019) emphasize core interventions—regular exercise, weight‑loss programs for overweight patients, and structured patient education—as foundational for long‑term osteoarthritis care【1】【5】.

After non‑pharmacologic measures, the recommended pharmacologic sequence is:
Intra‑articular corticosteroid injections are reserved only for acute flares; chronic or routine use is discouraged by the guidelines (EULAR 2003)【9】.